Fusion Antibodies plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| FAB.L | HCWB | ATORX.ST | BMEA | JSPR | IMM.L | |
|---|---|---|---|---|---|---|
| Market cap | 7.20M | 2.42M | 38.54M | 44.24M | 17.01M | 20.16M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.4 | -2.0 | -0.1 | -0.7 | -0.7 | 0.0 |
| Price/book | 4.4 | 0.2 | 0.3 | 3.7 | 10.2 | 10.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −54.72% | −94.21% | −99.41% | −53.43% | −75.38% | −67.26% |
| Today | −4.17% | −6.09% | +0.93% | −1.91% | +6.48% | −0.96% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All FAB.L news ›Fusion Antibodies lands contract with major US drugmaker
Fusion Antibodies plc (AIM: FAB) has secured a new contract worth more than £85,000 with an existing US pharmaceutical client, strengthening its commercial relationship with a major industry customer and supporting its strategy to grow…
Fusion Antibodies plc Announces Grant of Canadian Patent For OptiMAL
Fusion Antibodies plc announced that the Company's patent application no. CA 3115150 has been granted by the Canadian Intellectual Property Office. The grant of the Patent follows the receipt of a... Fusion Antibodies plc announced that…
Fusion Antibodies Receives Notice of Allowance for Canadian Patent Application Covering Antibody Library and Method
Fusion Antibodies plc announced that the Canadian Intellectual Property Office has issued a notice of allowance in respect of the Company's Canadian patent application no. 3,115,150. The Patent... Fusion Antibodies plc announced that the…
Fusion Antibodies plc Auditor Raises 'Going Concern' Doubt
Fusion Antibodies plc filed its Annual on Sep 22, 2026 for the period ending Mar 31, 2026. In this report its auditor, Price Bailey LLP, gave a qualified opinion expressing doubt that the company can... Biotechnology & Medical Research…
Fusion Antibodies Announces New TGE And Cryoem Project With US Pharma Client
TradingView Fusion Antibodies Announces New TGE And Cryoem Project With US Pharma Client
Fusion Antibodies Warns on H1 Trading but Flags Progress in DR5 Programme and OptiMAL Platform
The latest update is out from Fusion Antibodies Plc ( (GB:FAB) ). Spark’s Take on FAB Stock According to Spark, TipRanks’ AI Analyst, FAB is a Neutral. The score is held down primarily by weak financial performance—large ongoing losses and…
REG - Fusion Antibodies - Result of AGM
("Fusion" or the "Company") Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the annual general meeting…
REG - Fusion Antibodies - AGM statement H1 trading and research update
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 ("MAR"). With the publication of this announcement…
Transcript : Fusion Antibodies plc, 2026 Earnings Call, Sep 15, 2026
Presentation Operator MessageOperator Good morning. Welcome to the Fusion Antibodies plc Investor Presentation. [Operator Instructions] Before we begin, I'd like to submit the following poll. And Transcript : Fusion Antibodies plc, 2026…
Fusion Antibodies Gets Australian Patent Application Acceptance Notice
Fusion Antibodies received a notice of allowance from IP Australia for a patent application covering two families of antibodies and methods for designing antibody libraries, according to a... Biotechnology & Medical Research Fusion…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com6
- tradingview.com3
- share-talk.com1
- tipranks.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.